Robert W. Baird reiterated their hold rating on shares of Laboratory Corporation of America Holdings (NYSE:LH) in a research note issued to investors on Tuesday morning. The brokerage currently has a $166.00 target price on the medical research company’s stock.

Other research analysts have also recently issued reports about the stock. Canaccord Genuity reissued a buy rating and set a $180.00 price objective (up from $175.00) on shares of Laboratory Corporation of America Holdings in a report on Monday, September 11th. ValuEngine raised shares of Laboratory Corporation of America Holdings from a hold rating to a buy rating in a report on Wednesday, September 6th. Craig Hallum reissued a buy rating and set a $179.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a hold rating to a buy rating and set a $173.00 target price for the company in a research report on Thursday, September 21st. Finally, SunTrust Banks, Inc. restated a buy rating and set a $190.00 target price on shares of Laboratory Corporation of America Holdings in a research report on Thursday, October 12th. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Laboratory Corporation of America Holdings currently has an average rating of Buy and a consensus target price of $170.31.

Laboratory Corporation of America Holdings (LH) traded up 0.26% on Tuesday, hitting $151.72. 692,597 shares of the stock were exchanged. The stock has a market cap of $15.45 billion, a price-to-earnings ratio of 21.25 and a beta of 0.92. Laboratory Corporation of America Holdings has a 12 month low of $119.51 and a 12 month high of $164.22. The company has a 50-day moving average of $152.76 and a 200-day moving average of $149.09.

Laboratory Corporation of America Holdings (NYSE:LH) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The firm had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.47 billion. During the same period in the previous year, the company earned $2.36 earnings per share. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. On average, equities analysts predict that Laboratory Corporation of America Holdings will post $9.51 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/21/laboratory-corporation-of-america-holdings-lh-earns-hold-rating-from-robert-w-baird.html.

In other Laboratory Corporation of America Holdings news, CEO David P. King sold 44,687 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $156.86, for a total value of $7,009,602.82. Following the completion of the transaction, the chief executive officer now directly owns 258,753 shares in the company, valued at $40,587,995.58. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider F Samuel Eberts III sold 31,500 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $155.22, for a total transaction of $4,889,430.00. Following the completion of the transaction, the insider now owns 31,894 shares of the company’s stock, valued at $4,950,586.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 222,968 shares of company stock valued at $34,980,922. Company insiders own 0.90% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the business. Smith Graham & Co. Investment Advisors LP bought a new position in shares of Laboratory Corporation of America Holdings in the third quarter worth approximately $1,643,000. Rockefeller Financial Services Inc. boosted its position in shares of Laboratory Corporation of America Holdings by 1,494.8% in the third quarter. Rockefeller Financial Services Inc. now owns 2,137 shares of the medical research company’s stock worth $323,000 after purchasing an additional 2,003 shares during the period. Fisher Asset Management LLC bought a new position in shares of Laboratory Corporation of America Holdings in the third quarter worth approximately $9,888,000. P.R. Herzig & Co. Inc. bought a new position in shares of Laboratory Corporation of America Holdings in the third quarter worth approximately $226,000. Finally, Robeco Institutional Asset Management B.V. boosted its position in shares of Laboratory Corporation of America Holdings by 13.0% in the third quarter. Robeco Institutional Asset Management B.V. now owns 16,319 shares of the medical research company’s stock worth $2,464,000 after purchasing an additional 1,880 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.